Literature DB >> 22652844

Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.

Duangnate Rojanaporn1, Swathi Kaliki, Carlos G Bianciotto, Juan C Iturralde, Emil A Say, Carol L Shields.   

Abstract

OBJECTIVE: To assess the long-term results of chemotherapy for cavitary retinoblastoma.
METHODS: Retrospective, nonrandomized, interventional case series of 26 cavitary retinoblastomas in 25 eyes of 24 patients. Retinoblastomas were treated with intravenous chemoreduction and/or intra-arterial chemotherapy. Main outcome measures included tumor control, globe salvage, and metastasis.
RESULTS: Of 24 patients with cavitary retinoblastoma, the mean age at diagnosis was 16 months. The mean number of cavitary tumors per eye was 1 (median, 1; range, 1-2), with a mean tumor basal diameter of 13 (median, 13; range, 7-24) mm and mean tumor thickness of 7 (median, 6; range, 3-17) mm. The mean number of cavities per tumor was 2 (median, 2; range, 1-5), with a mean cavity diameter of 3 (median, 2; range, 1-10) mm. Related features included vitreous seeds in 7 tumors (27%), subretinal seeds in 6 (23%), and subretinal fluid in 13 (50%). Intravenous chemoreduction was used in 23 tumors (88%); intra-arterial chemotherapy, in 2 (8%); and both, in 1 (4%). After treatment, the mean reduction in tumor base was 22% and mean reduction in tumor thickness was 29%. Despite minimal reduction, tumor recurrence was noted in only 1 eye (4%), globe salvage was achieved in 22 (88%), and there were no cases of metastasis or death during 49 (range, 6-189) months of follow-up.
CONCLUSION: Despite minimal visible tumor response to chemotherapy, cavitary retinoblastoma displays relatively stable long-term results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652844     DOI: 10.1001/archophthalmol.2011.2825

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Cavitary retinoblastoma: clinical observations.

Authors:  Pukhraj Rishi; Unnati Sharma; Tarun Sharma
Journal:  Eye (Lond)       Date:  2019-09-18       Impact factor: 3.775

2.  Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma.

Authors:  John T Lucas; Rose McGee; Catherine A Billups; Ibrahim Qaddoumi; Thomas E Merchant; Rachel C Brennan; Jiangrong Wu; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2018-06-28       Impact factor: 4.638

3.  Intra-arterial Chemotherapy as Primary Treatment for Cavitary Retinoblastoma: Excellent Response in Eight Tumors.

Authors:  Yuxi Zheng; Michael T Froehler; Debra L Friedman; Anthony B Daniels
Journal:  Ophthalmol Retina       Date:  2020-08-24

4.  Histopathologic Observations of Eyes in Exenterated Orbits After Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Adenoid Cystic Carcinoma of the Lacrimal Gland.

Authors:  Sophie D Liao; Benjamin P Erickson; Neha Kapila; Sander R Dubovy; David T Tse
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2021 May-Jun 01       Impact factor: 2.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.